Cheap-to-serve incremental business: management says the next tranche of volume costs it almost nothing extra
The model's full reasoning — Q3 2018 call → NOWe need to determine if management conveys that the cost of serving the next increment of business has become unusually low, with both halves present: (1) next unit cheap to serve because base already built and paid for, and (2) more of that business is already arriving now. Let's analyze the transcript. Management discusses strong revenue growth, investments in pipeline, and guidance updates. They mention R&D expenses, product gross margins, and infrastructure costs. They talk about the SurVeil agreement with Abbott, revenue from that, and progress in clinical trials. They also mention the Embolitech acquisition and thrombectomy platform. Key points: They raised revenue guidance and non-GAAP EPS guidance. They mention that R&D expense as a percentage of revenue was relatively unchanged, and they expect Q4 R&D to be in the mid to high 50s as a percentage of revenue. They talk about product gross margins being negatively impacted by mix and infrastructure costs in Ireland. They mention that they are investing in new product pipeline. Do they convey that incremental business is cheap? They talk about having a base, but they also talk about increasing R&D spending. They mention that they are prioritizing resources to support the SurVeil project. They talk about scaling up costs in Ireland. They don't explicitly say that the next unit of business is cheap to serve. They do mention that they have a strong balance sheet and cash flows, but that's not about incremental cost. They also talk about revenue from Abbott being recognized over time, but that's not about incremental cost. They mention that they are making progress on products and have regulatory clearances, but they don't say that additional business will ride on already-paid-for base without proportional spending. They do mention that they have a pipeline and are targeting regulatory filings, but that's future. They also talk about the thrombectomy technology acquisition and that they are working on prototypes, but that's new investment. They mention that they are updating guidance due to better than expected revenue performance, but that doesn't necessarily mean incremental cost is low. They talk about R&D expense being relatively unchanged as a percentage of revenue, but they expect it to accelerate in Q4. So they are not saying that costs are flattening while activity rises.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| TGLS | Tecnoglass Inc. | Q2 2023 | 2023-08-08 | A |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| HFWA | Heritage Financial Corporation | Q4 2021 | 2022-01-27 | A |
| AMC | AMC Entertainment Holdings, Inc. | Q2 2021 | 2021-08-09 | D |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| UMH | UMH Properties, Inc. | Q3 2018 | 2018-11-02 | C+ |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| SATS | EchoStar Corporation | Q1 2018 | 2018-05-10 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
SATS · Q1 2018 → YESThe question is about whether management conveys that the cost of serving the next increment of business has become unusually low, meaning additional volume can be delivered with already built and pai...NO The transcript shows management describing high growth with significant upfront acquisition costs, fixed costs leading to margin expansion as growth slows, and beams filling up faster than expected on Jupiter-2 (implying approaching capacity limits rather than excess capacity). However, there is no clear indication of an already-built, underutilized base where additional business is arriving on resources already paid for without new capacity investment. Instead, they highlight ongoing build-out (Jupiter-3 in 2021) and potential slowdowns, which aligns with the "NO" criteria for being near limits or in a growth cycle requiring new spending.
ATI · Q1 2018 → YESThe question is about whether management conveys that the cost of serving the next increment of business has become unusually low, meaning additional volume can be delivered with already built and pai...YES Management describes the HPMC segment’s leverage from “additional volume across our asset base” and “utilization increases across our isothermal and conventional forging assets” that already generated “significant incremental margin growth,” with next-generation jet engine sales up 65% and now at 48% of total jet engine sales. They state they are “well positioned both in capability and capacity to continue to benefit from these trends well into the future” after noting the fourth press is coming on stream in a couple of years.
UMH · Q3 2018 → YESThe question is about whether management conveys that the cost of serving the next increment of business has become unusually low, meaning additional volume can be delivered with already built and pai...YES The transcript shows management conveying exactly this situation: the company already owns 3,600 vacant sites (most acquired) plus 6,215 rental homes (93.3% occupied), so the next increment of rental-home business can be served on infrastructure already paid for and in place. They explicitly call the rental program “the most efficient way to fill the vacant sites,” and they are already adding 608 homes this year on track for 800, with Same-Property occupancy rising to 83.2% and expense ratios improving as occupancy climbs.